Document is current

Article History

Received: 25 February 2025

Accepted: 14 April 2025

First Online: 14 May 2025

Declarations

:

: Calvin N. Ho and Lila Bahadori are employees of AstraZeneca and may own stock/stock options. Marc Yale and Naomi Bishop have nothing to disclose. Caroline Roberts, Oren Meyers, and Julie Bailey are or were employees of IQVIA at the time of the study, which received funding from AstraZeneca for the conduct of this study; Caroline Roberts is currently an employee of Blue Fin Group, an IntegriChain Company, and Oren Meyers is currently an employee of GSK. Neil J. Korman has been an investigator for Abcentra, Amgen, Castle Bioscience, Celgene, Chemocentryx, Galderma, Kyowa Hakko Kirin Pharma, Menlo Therapeutics, and XBiotech; advisory board member for Boehringer Ingelheim and Sun Pharma; investigator and advisory board member for Argenx, Bristol Myers Squibb, Dermavant, Leo Pharma, Principia, Regeneron, Trevi, and UCB; investigator, advisory board member, and speaker for AbbVie and Eli Lilly; consultant for AstraZeneca; advisory board member and speaker for Janssen; and advisory board member, speaker, and consultant for Novartis.

: This study was granted Institutional Review Board approval from WCG Clinical, Inc (approval number: 20220923), and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.